Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

CARABELA trial results suggest that 12 months of letrozole/abemaciclib may not offer similar efficacy to that of chemotherapy in achieving RCB 0 to I. However, in less proliferative tumors (RS <26 or Ki-67 <30%), outcomes were comparable, suggesting that letrozole/abemaciclib could replace (neo)adjuvant chemotherapy in selected patients.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-12-12
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2435
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

Isaura Fernández, Isabel Álvarez, Carmen Hinojo, Federico Rojo et al.
Clinical Cancer Research
Advanced Breast Cancer Therapies
article

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

Isaura Fernández, Isabel Álvarez, Carmen Hinojo, Federico Rojo, Begoña Bermejo, José Á. García-Sáenz, Miguel Gil‐Gil, Ana Santaballa, Emilio Alba, Elisa García-Garré, Juan de la Haba-Rodríguez, Ángel Guerrero‐Zotano, Susana Bezares, Eva Pérez, Pedro Sánchez‐Rovira, José Ponce, José Ignacio Chacón, Manuel Ruíz-Borrego, Santiago González-Santiago, Eduardo Martínez de Dueñas, Rosalía Caballero, Noelia Martínez-Jáñez, Sonia Del Barco, B. A. Hernando Fernandez de Araguiz, Miguel Martín, Raquel Andrés, Marta González, Maribel Casas
article en

Abstract

CARABELA trial results suggest that 12 months of letrozole/abemaciclib may not offer similar efficacy to that of chemotherapy in achieving RCB 0 to I. However, in less proliferative tumors (RS <26 or Ki-67 <30%), outcomes were comparable, suggesting that letrozole/abemaciclib could replace (neo)adjuvant chemotherapy in selected patients.

Clinical Cancer ResearchVol. 32(5)
University of Alicante (ES), Catalan Institute for Water Research (ES), ProMedica Toledo Hospital (US), University Hospital Complex Of Vigo (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Clínico San Carlos (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital General Universitario Morales Meseguer (ES), Clínica Girona (ES), Instituto Maimónides de Investigación Biomédica de Córdoba (ES), Hospital Clínico Universitario de Valencia (ES), Consorcio Hospitalario Provincial de Castellón (ES), Marqués de Valdecilla University Hospital (ES), Biogipuzkoa Health Research Institute (ES), Fundación Instituto Valenciano de Oncología (ES), Institut Català d'Oncologia (ES), Hospital San Pedro de Alcántara (ES), Instituto de Investigación Marqués de Valdecilla (ES), Hospital Universitario de Burgos (ES), Complejo Hospitalario de Jaén (ES), Hospital Universitario Reina Sofía (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Clínico Universitario Lozano Blesa (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Centro de Implantología Cirugía Oral y Maxilofacial (ES), Donostiako Unibertsitate Ospitalea (ES), Complexo Hospitalario Universitario A Coruña (ES), Instituto Murciano de Investigación Biosanitaria (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), INCLIVA Health Research Institute (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Complejo Hospitalario de Cáceres (ES), Hospital Universitario Ramón y Cajal (ES), Complejo Hospitalario Universitario de Toledo (ES), GEICAM – Spanish Breast Cancer Group (ES), Instituto de Investigación Biomédica de Málaga (ES), Universidad Autónoma de Madrid (ES)
Eli Lilly and Company
Openalex Percentile: Top 41%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.